-

Visus Therapeutics to Present at 2023 JMP Securities Life Science Conference

Company Announced Positive Topline Clinical Data from Phase 3 Pivotal BRIO-I Trial of BRIMOCHOL™ PF for the Treatment of Presbyopia.

BRIMOCHOL PF met its prespecified FDA primary endpoint for binocular near visual acuity across multiple time points, starting at hour 1, versus active controls, and was well-tolerated with no significant adverse events.

Non-surgical drug candidate to reverse cataracts expected to advance into clinical development in 2023.

SEATTLE & IRVINE, Calif--(BUSINESS WIRE)--Visus Therapeutics Inc., a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapies for indications in the front and back of the eye, today announced that Ben Bergo, co-founder, and chief executive officer, will present at the JMP Securities Life Science Conference on May 15th, 2023, at the New York Hilton Midtown.

The presentation is scheduled for 10:00 AM Eastern Time on Monday, May 15th. A live webcast of the presentation will be available at: https://bit.ly/JMPwebcast.

Mr. Bergo will also be available for one-on-one meetings with investors on May 15th and May 16th.

About Visus Therapeutics

With offices in Seattle, Wash., and Irvine, Calif., Visus Therapeutics is a clinical-stage biopharmaceutical company focused on developing multi-targeted ophthalmic therapeutics for the front and back of the eye. The company is developing novel, pupil-modulating therapeutics designed to correct the loss of near vision associated with presbyopia. In parallel, Visus is advancing its pipeline of early-stage ophthalmic drug candidates engineered to preserve and restore visual function associated with the leading causes of vision loss including cataract and presbyopia, ocular surface and corneal disease, glaucoma, and age-related macular degeneration. Visit: visustx.com and follow us on LinkedIn, Twitter, and Instagram.

Contacts

Media:

Business & Biotech Press
James Heins
jheins@lavoiehealthscience.com
(646) 491-7042

Investor Relations
Paul Sagan
Psagan@lavoiehealthscience.com
(617) 865-0041

Eye Care Trade Press
Michele Gray
michele@mgraycommunications.com
(917) 449-9250

Visus Therapeutics Inc.


Release Summary
Visus Therapeutics to present at the 2023 JMP Securities Life Science Conference on May 15. A live webcast of the presentation will be available.
Release Versions

Contacts

Media:

Business & Biotech Press
James Heins
jheins@lavoiehealthscience.com
(646) 491-7042

Investor Relations
Paul Sagan
Psagan@lavoiehealthscience.com
(617) 865-0041

Eye Care Trade Press
Michele Gray
michele@mgraycommunications.com
(917) 449-9250

Social Media Profiles
More News From Visus Therapeutics Inc.

Tenpoint Therapeutics Ltd. Announces FDA Acceptance of New Drug Application for BRIMOCHOL™ PF for the Treatment of Presbyopia

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics Ltd. announces FDA acceptance of New Drug Application for BRIMOCHOL™ PF for the treatment of presbyopia...

Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics Ltd. Appoints Melissa Epperly as Chief Financial Officer....

Tenpoint Therapeutics Ltd. to Participate at Citi Biotech Private Access Day

LONDON & SEATTLE--(BUSINESS WIRE)--Tenpoint Therapeutics, Ltd. (“Tenpoint”), a global, clinical-stage biotechnology company focused on developing groundbreaking treatments to rejuvenate vision in the aging eye, today announced that Henric Bjarke, Chief Executive Officer of Tenpoint Therapeutics, will participate in one-on-one meetings at the virtual Citi Biotech Private Access Day on April 24. About Tenpoint Therapeutics Tenpoint Therapeutics Ltd. is a global, clinical-stage biotech company dev...
Back to Newsroom